(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 May 2014 (15.05.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/074528 A3

(51) **International Patent Classification**:
C07K 16/00 (2006.01) *A61K 39/40* (2006.01)
C12P 21/08 (2006.01)

(21) **International Application Number**:
PCT/US2013/068609

(22) **International Filing Date**:
6 November 2013 (06.11.2013)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/723,192 6 November 2012 (06.11.2012) US

(71) **Applicant**: **MEDIMMUNE, LLC** [US/US]; One Medlmmune Way, Gaithersburg, MD 20878 (US).

(72) **Inventors**: **DIGIANDOMENICO, Antonio**; c/o Medimmune, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US). **WARRENER, Paul**; c/o Medimmune, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US). **STOVER, Charles**; c/o Medimmune, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US). **SELLMAN, Bret**; c/o Medimmune, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US). **MINTER, Ralph**; c/o Medimmune Limited, Milstein Building, Granta Park, Cambridge CB21 6GH (GB). **GUILLARD, Sandrine**; c/o Medimmune Limited, Milstein Building, Granta Park, Cambridge CB21 6GH (GB). **RUST, Steven**; c/o Medimmune Limited, Milstein Building, Granta Park, Cambridge CB21 6GH (GB). **TOMICH, Miaden**; 117 Atheton Drive, Exton, PA 19341 (US). **VENKATRAMAN, Vignesh**; c/o Medimmune Limited, Milstein Building, Granta Park, Cambridge CB21 6GH (GB). **VARKEY, Reena**; c/o Medimmune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US). **PENG, Li**; c/o Medimmune, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US). **DAMS-CHRODER, Melissa**; c/o Medimmune, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US). **CHOWDHURY, Partha**; c/o Medimmune, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US). **DI-MASI, Nazzareno**; c/o Medimmune, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US). **FLEMING, Ryan**; c/o Medimmune, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US). **BEZABEH, Binyam**; c/o Medimmune, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US). **GAO, Changshou**; c/o Medimmune, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US).

(74) **Agents**: **COHEN, Jared** et al.; Medimmune, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,

[Continued on next page]

(54) **Title**: COMBINATION THERAPIES USING ANTI-*PSEUDOMONAS* PSL AND PCRV BINDING MOLECULES




FIG. 1

(57) **Abstract**: Using anti-Pseudomonas PsI and PcrV binding molecules and related compositions in prevention and treatment of Pseudomonas infection are disclosed. Further provided are isolated binding molecules which specifically bind to Pseudomonas PcrV or Pseudomonas PsI, and bispecific antibodies that specifically bind to Pseudomonas PcrV and Pseudomonas PsI. The sequences of heavy chain and light chain as well as sequences of complementarity determining regions (CDRs) of these binding molecules are further disclosed.

WO 2014/074528 A3

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) **Date of publication of the international search report**:
3 July 2014